Nalotimagene carmaleucel - MolMed

Alternative Names: Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes; HSV-Tk; TBI-0301; TK; TK cell therapy - MolMed; Zalmoxis

Latest Information Update: 05 Mar 2018

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator MolMed
Class Cell therapies; Gene therapies; T lymphocyte cell therapies
Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Haematological malignancies; Leukaemia
New Molecular Entity No

Highest Development Phases

Marketed Leukaemia

Most Recent Events

24 Jun 2018 Biomarkers information updated
01 Mar 2018 Launched for Leukaemia (Adjunctive treatment) in Italy (IV)
26 Feb 2018 Launched for Leukaemia (Adjunctive treatment) in Germany (IV) before February 2018

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight